BUSINESS WIRE: ONWARD Announces Participation at Upcoming Investor Events in September
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
EINDHOVEN, Netherlands & LAUSANNE, Switzerland --(BUSINESS WIRE)-- 07.09.2022 --
ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today announced that management will participate in the following upcoming investor events in September:
- KBC Securities Virtual Life Sciences Conference
September 16, 2022
Dave Marver, CEO, and Lara Smith Weber, CFO, will participate in the conference and give a company presentation.
- btov Portfolio Day
September 21, 2022
Lara Smith Weber, CFO, will give a company presentation.
Information on upcoming conferences is available in the investor section of the ONWARD website at https://ir.onwd.com/news-events.
About ONWARD Medical
ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARCIM) or external (ARCEX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the U.S. FDA, encompassing both ARCIM and ARCEX. ARCEX is an external, non-invasive platform consisting of a wearable stimulator and wireless programmer. The company’s first pivotal trial, called Up-LIFT, evaluating the ability of ARCEX Therapy to improve upper extremity strength and function, completed enrollment in December 2021 with 65 subjects worldwide. Topline results are expected in September 2022. ARCIM consists of an implantable pulse generator and lead placed near the spinal cord. The company completed its first-in-human use of the ARCIM neurostimulator in May 2022.
ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains a significant team in Lausanne, Switzerland, and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com. To access our 2022 Financial Calendar, please visit IR.ONWD.com.
Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
For Company Enquiries:
For Media Enquiries:
MC Services AG
US: Laurie Doyle, P: +1 339 832 0752
Europe: Dr. Claudia Riedl, Kaja Skorka, P: +49 89 210 228 0
For Investor Enquiries: